Literature DB >> 31863212

A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.

Leanna M Wise1, Daniel G Arkfeld2.   

Abstract

Primary Sjogren's syndrome (pSS) can have a myriad of presentations, ranging from mild xerostomia to more diffuse systemic involvement. It is well established that pSS is associated with a variety of pulmonary pathologies, and it is also known that pSS patients are at higher risk for lymphoma development. Here, we present an unusual case of a woman with primary Sjogren's syndrome who had both diffuse cystic lung disease as well as extranodal MALT lymphoma, successfully treated for both conditions with the CD-20 monoclonal antibody rituximab.

Entities:  

Keywords:  Cystic lung disease; Lymphoma; Rituximab; Sjogren’s syndrome

Year:  2019        PMID: 31863212     DOI: 10.1007/s10067-019-04886-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  50 in total

1.  Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests.

Authors:  M Uffmann; H P Kiener; A A Bankier; M M Baldt; T Zontsich; C J Herold
Journal:  J Thorac Imaging       Date:  2001-10       Impact factor: 3.000

Review 2.  Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management.

Authors:  Gaetane Nocturne; Xavier Mariette
Journal:  Br J Haematol       Date:  2014-10-15       Impact factor: 6.998

3.  Primary Sjögren's syndrome associated with non-Hodgkin's lymphoma of salivary gland and cystic lung disease.

Authors:  Ksenija Kocijancic; Igor Kocijancic
Journal:  Coll Antropol       Date:  2006-12

4.  Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors.

Authors:  Carlos D Martínez-Balzano; Sunkaru Touray; Scott Kopec
Journal:  Chest       Date:  2016-05-24       Impact factor: 9.410

Review 5.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

6.  Cystic lung disease in Sjögren's syndrome: An observational study.

Authors:  Sarah Lechtman; Marie-Pierre Debray; Bruno Crestani; Catherine Bancal; Muriel Hourseau; Antoine Dossier; Jean-François Alexandra; Marie-Paule Chauveheid; Thomas Papo; Karim Sacre
Journal:  Joint Bone Spine       Date:  2016-09-19       Impact factor: 4.929

7.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Nicolas Cagnard; Carlo Lucchesi; Franck Letourneur; Sylvie Mistou; Thierry Lazure; Sebastien Jacques; Nathalie Ba; Marc Ittah; Christine Lepajolec; Marc Labetoulle; Marc Ardizzone; Jean Sibilia; Catherine Fournier; Gilles Chiocchia; Xavier Mariette
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 8.  Lymphocytic Interstitial Pneumonia.

Authors:  Tanmay S Panchabhai; Carol Farver; Kristin B Highland
Journal:  Clin Chest Med       Date:  2016-06-25       Impact factor: 2.878

9.  Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome.

Authors:  Shinya Tasaki; Katsuya Suzuki; Ayumi Nishikawa; Yoshiaki Kassai; Maiko Takiguchi; Rina Kurisu; Yuumi Okuzono; Takahiro Miyazaki; Masaru Takeshita; Keiko Yoshimoto; Hidekata Yasuoka; Kunihiro Yamaoka; Kazuhiro Ikeura; Kazuyuki Tsunoda; Rimpei Morita; Akihiko Yoshimura; Hiroyoshi Toyoshiba; Tsutomu Takeuchi
Journal:  Ann Rheum Dis       Date:  2017-05-18       Impact factor: 19.103

10.  Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.

Authors:  G Nocturne; A Virone; Wan-Fai Ng; V Le Guern; E Hachulla; D Cornec; C Daien; O Vittecoq; B Bienvenu; C Marcelli; D Wendling; Z Amoura; R Dhote; C Lavigne; R Fior; J E Gottenberg; R Seror; X Mariette
Journal:  Arthritis Rheumatol       Date:  2016-04       Impact factor: 10.995

View more
  1 in total

1.  Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study.

Authors:  Wei Yan; Bin Wu; Ai-Jun Liao; Wei Yang; Hui-Han Wang
Journal:  Ann Hematol       Date:  2021-01-22       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.